<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005104</url>
  </required_header>
  <id_info>
    <org_study_id>199/14915</org_study_id>
    <secondary_id>UVA-HIC-7538</secondary_id>
    <secondary_id>UVA-WSE026</secondary_id>
    <nct_id>NCT00005104</nct_id>
  </id_info>
  <brief_title>Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine whether reduction of serum insulin levels by metformin increases ovulatory&#xD;
      response to clomiphene citrate in women with polycystic ovary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.&#xD;
      Patients are randomized to one of two treatment arms.&#xD;
&#xD;
      Patients receive oral metformin or oral placebo three times daily for 7 weeks. Patients&#xD;
      remaining anovulatory by day 49 receive metformin or placebo plus escalating doses of oral&#xD;
      clomiphene citrate daily for 5 consecutive days, beginning on days 50, 80, and 110. Following&#xD;
      ovulation, treatment with clomiphene citrate and metformin or placebo continues until 6&#xD;
      ovulatory cycles occur, pregnancy occurs, or anovulation persists. Patients receiving the&#xD;
      placebo arm who have not ovulated on the highest dose of clomiphene citrate may be crossed&#xD;
      over to receive metformin after a 6 week washout.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>99</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Hyperinsulinism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Patients with chronic anovulation due to polycystic ovary syndrome (PCOS) who have failed&#xD;
        clomiphene citrate&#xD;
&#xD;
        Must have oligoovulation and hyperandrogenemia&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        Endocrine therapy: At least 2 months since prior clomiphene citrate&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 2 months since prior standard therapy (including over the counter drugs)&#xD;
&#xD;
          -  At least 2 months since prior investigational drugs&#xD;
&#xD;
          -  Prior multi/prenatal vitamins allowed&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hematopoietic: Hematocrit greater than 38%&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Liver function normal&#xD;
&#xD;
          -  No clinically significant hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No clinically significant renal disease&#xD;
&#xD;
          -  Creatinine less than 1.4 mg/dL&#xD;
&#xD;
          -  No proteinuria&#xD;
&#xD;
        Cardiovascular: No clinically significant cardiac disease&#xD;
&#xD;
        Pulmonary: No clinically significant pulmonary disease&#xD;
&#xD;
        Hormonal:&#xD;
&#xD;
          -  Thyroid function normal&#xD;
&#xD;
          -  Prolactin normal&#xD;
&#xD;
          -  Estradiol normal&#xD;
&#xD;
          -  Fasting 17 alpha-hydroxy progesterone less than 200 ng/dL OR No late onset adrenal&#xD;
             hyperplasia 21 alpha-hydroxylase deficiency&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Male partner must have a normal semen analysis by WHO criteria&#xD;
&#xD;
          -  Must be in acceptable health by interview, medical history, physical exam, and&#xD;
             laboratory tests&#xD;
&#xD;
          -  No diabetes mellitus&#xD;
&#xD;
          -  No clinically significant neurologic, psychiatric, infectious, neoplastic, or&#xD;
             metabolic disease&#xD;
&#xD;
          -  No clinically significant malignant disease except nonmelanomatous skin cancer&#xD;
&#xD;
          -  At least 1 year since any prior drug abuse or alcoholism&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William S. Evans</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University School of Medicine</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University - St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia School of Medicine</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Alma Mater</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>April 6, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>endocrine disorders</keyword>
  <keyword>hyperinsulinism</keyword>
  <keyword>polycystic ovarian syndrome</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

